Scholars Central

Conference abstractPublished 28 Aug 2023

Clinical efficacy and pregnancy improvement by Linagliptin and Empagliflozin as an alternative to Metformin for treatment of infertile women with polycystic ovarian syndrome

Authors: Haidy M. Sami, Noha Alaa Hamdy, Hanan Nabil, Ahmed I. ElMallah

Delta University Drug Information Center, Egypt Alexandria University, Egypt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Problem/Background: Polycystic ovarian syndrome (PCOS) is one of the most prevalent neuroendocrine disorders of the reproductive system. PCOS exhibits heterogeneity of symptoms as a result of the involvement of multiple pathways and the lack of utilized clues. Metformin increases insulin sensitivity, but it is associated with unsatisfied benefits on fertility in PCOS. Recent studies have reported that Dipeptidyl-Peptidase-4 Inhibitors (DPP-4is), Sodium/glucose cotransporter-2 inhibitors (SGLT-2is) improve ovarian cycles in PCOS. The purpose of this study is to compare the efficacy of Empagliflozin (SGLT-2i) or Linagliptin (DPP-4i) versus Metformin for treatment of infertile PCOS women. Methodology: In this randomized, controlled trial, 135 PCOS women (20-36 years-old) were classified into three-groups: group-1, involved 45 PCOS patients received Metformin (1500 mg orally/day); group-2, consisted of 45 PCOS patients received Empagliflozin (25 mg orally/day); and group-3, included 45 PCOS patients received Linagliptin (10 mg orally/day). Patients were recruited from the Gynecologic and Obstetric outpatient’s clinics, Mansoura-University-Hospitals, Egypt and assessed before, 3-months after intervention and 6-months of follow-up for determination of menstrual-cycle, dermatologic-signs, ultrasound-characteristics, pregnancyrate, FSH, LH, AMH, progesterone, total-testosterone, SHBG, FAI, DHEAS, HbA1C% and HOMA-IR. Data were statistically analyzed by one-way-analysis of variance (ANOVA), (p < 0.05). Findings: The current study reported that the potential roles of Linagliptin or Empagliflozin versus Metformin in improvement of ovulation and fertility in PCOS. As compared to group-1 and 2, group-3 (Linagliptin) showed significant difference in most measured parameters after 3-months of therapy and 6-months of follow-up (p<0.05), including significant improvement in menstrual regularity (33.3%, 35.6%, 95.6%), respectively and pregnancy rate (31.1%, 22.2%, 84.4%), respectively. Conclusion: This research came to clarify the emerging roles of these pharmacotherapies in treatment of infertile PCOS patients. The current study indicates that Linagliptin is a promising approach in treatment of PCOS and prevention of its related complication, also other DPP-4is could be examined

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalReproductive System & Sexual Disorders: Current Research
  • SubjectReproductive Medicine & Gynaecology
  • BylineArticles whose byline prints “Haidy M. Sami”
  • BylineArticles whose byline prints “Noha Alaa Hamdy”
  • BylineArticles whose byline prints “Hanan Nabil”
  • BylineArticles whose byline prints “Ahmed I. ElMallah”